Bloom Lab Profile picture
5 Jan, 28 tweets, 16 min read
We mapped how all mutations to #SARSCoV2 receptor-binding domain (RBD) affect recognition by convalescent polyclonal human sera (biorxiv.org/content/10.110…).

Among implications: E484K (South African lineage) worrying for immune escape; RBD mutations in UK lineage less so (1/n).
We first determined where in #SARSCoV2 mutations most affect viral neutralization. @veeslerlab had reported RBD-binding antibodies responsible for most neut activity of human sera: sciencedirect.com/science/articl…. We validated w sera from @HelenChuMD's HAARVI cohort (below) (2/n)
Since RBD is main antigenic region (although NTD also important, see below), @AllieGreaney applied method she & @tylernstarr developed for monoclonal antibodies (sciencedirect.com/science/articl…) to map how all mutations to RBD affect binding by *polyclonal* human sera (3/n)
Below are escape maps for sera of 4 people (preprint has more). Tall letters mean mutations greatly reduce serum binding. 3 main sera epitopes in RBD. Most important centers on E484 (dark blue), another is 443-450 loop (light blue), last is distal from ACE2 (orange) (4/n)
But lots of variation in specificity of anti-RBD immunity among people. For instance, image in previous tweet shows subjects C (& to lesser degree I) focus on E484, subject G focuses on 443-450 loop, and subject K has broad binding not much affected by any single mutation. (5/n)
Key results validate in neutralization assays. Mutations at E484 greatly reduce neutralization (>10 fold) by sera from some individuals (examples below). Unfortunately, the South African lineage has E484K, as do some other isolates from elsewhere. (6/n)
But as escape maps show, effects of mutations differ across individuals. For subject G (below), serum neutralization not much affected by E484K, but reduced >10-fold by G446V. And some sera not much affected by any RBD mutation (eg, subject K in 4th tweet in thread). (7/n)
Also, sometimes effects of mutations change over time for same individual as immune response matures. For subject G below, mutations in 443-450 loop cause big reduction in serum antibody binding at day 18 post-symptom onset, but much less effect several months later. (8/n)
Here are neutralization assays validating maps in prior tweet: G446V greatly reduced neutralization by subject G's sera at day 18, but not day 94 (note total overall neut titers change too).

So heterogeneity both across people and for a single person over time. (9/n)
But can make some generalizations based on examples above + rest of data in pre-print. On average, mutations at E484 have biggest effect on polyclonal sera. Also large effects at sites structurally adjacent to E484 (pre-print has list), and in 443-450 loop for some sera. (10/n)
These results broadly consistent w other studies that selected RBD mutations that greatly reduce neut by polyclonal sera. See papers by @PaulBieniasz @theodora_nyc @vsv512 @e_andreano @McLellan_Lab: biorxiv.org/content/10.110…, biorxiv.org/content/10.110…, elifesciences.org/articles/61312 (11/n)
We do not see strong antigenic effects of N501Y RBD mutation in UK viral lineage, consistent with these data from @TheMenacheryLab (). Note that N501Y could affect transmissibility, and UK lineage also has NTD mutations (more on that below). (12/n)
Here's plot of how mutating RBD sites affects average serum binding (y-axis) vs frequency of mutations (x-axis). E484K in S African lineage most worrying. But others affect some serum to various degrees & no such thing as "average" human when it comes to serum specificity (13/n)
Importantly, we only looked at RBD muts, since majority of neut activity of most sera from RBD antibodies (2nd tweet of thread). But NTD muts also important; see @10queues @mccarthy_kr @GuptaR_lab @e_andreano @McLellan_Lab: biorxiv.org/content/10.110…, medrxiv.org/content/10.110… (14/n)
This relative role of RBD & NTD mutations consistent w historical evolution of common-cold CoV-229E, where mutations concentrated in receptor-binding loops of RBD, but also in parts of NTD. Here is plot of mutational variability in CoV-229E spike: (15/n)
What do results mean for possible #SARSCoV2 immune escape? Certainly mutations like E484K are concerning. But they *reduce* neut activity, they don't ablate it. Again, look at CoV-229E: takes years of evolution to escape serum neut of most people (16/n)
Heterogeneity of mutation effects across sera could be blessing, as mutations that reduce neutralization by some people won't affect others. Look below at how differently evolution of CoV-229E erodes neutralization by different people (Fig 2A of biorxiv.org/content/10.110…) (17/n)
Heterogeneity also shown by @e_andreano @RommieAmaro @McLellan_Lab, who found multiple mutations that greatly (300-fold) reduce neut of #SARSCoV2 by one human serum but often only modestly (a few fold) affect other sera: biorxiv.org/content/10.110… (18/n)
Scientifically, we see two priorities going forward: (a) Perform similar studies of vaccine sera. Is vaccine immunity affected by mutations similarly to natural immunity? (b) Monitor for antigenic mutations so vaccines can eventually be updated if needed. (19/n)
But biggest priority is vaccinate! Despite above, I'm confident current vaccines will be useful for quite a while. Reasons: (a) even worst mutations (ie, E484) only erode neut activity of some sera, don't eliminate it for any, (b) current vaccines elicit strong immunity... (20/n)
... (c) evidence in animals (& from humans after 1st vaccine dose) that modest immunity can blunt disease, (d) natural immunity to seasonal CoV provides some homologous protection for 3+ years even though they evolve too (see wellcomeopenresearch.org/articles/5-52) (21/n)
Finally, most credit goes to @AllieGreaney, the outstanding grad student who led our study. She worked with Andrea Loes, @khdcrawford, @tylernstarr, & Keara Malone. @HelenChuMD was our invaluable clinical collaborator, and thanks to the volunteers in her HAARVI cohort (22/n)
I'd also like to call out the important work by @houzhou @Tuliodna and cowoerkers in characterizing lineage 501Y.V2 initially identified in South Africa, which carries RBD mutations including E484K, which our study suggests has an antigenic effect: medrxiv.org/content/10.110… (23/n)
Our functional work is potentially useful because the high-quality viral surveillance and rapid reporting of data exemplified by their study.

I'd also like to correct terminology earlier in this Tweet chain. It is lineage 501Y.V2, initially identified in South Africa. (24/n)
It should be referred by full lineage, not country as in my earlier Tweet. In addition, E484K has been independently observed in viruses from other locations, so any antigenic impacts of this mutation is *not* a concern confined to any country or viral lineage. (25/n)
One more Tweet to share data by @firefoxx66 inspired by useful comments from @Tuliodna. Please read this:

Key implication: the E484K mutation was most prominently reported by @Tuliodna in the 501Y.V2 lineage first identified in South Africa. (26/n)
But importantly, muts at E484 arisen multiple times in several countries over last 9 months. Our functional work (& others cited above) show E484 muts antigenically important. And surveillance by @Tuliodna @rjlessells @atrvlncc & others show this mutation is circulating (27/n)
But because this mutation has arisen multiple times in multiple locations, it is not a concern confined to any particular country. Instead, globally important to continue to monitor evolution, characterize mutations, & assess any eventual implications for vaccine updates. (28/n)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Bloom Lab

Bloom Lab Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @jbloom_lab

5 Jan
Here's plot of how mutating RBD sites affects average serum binding (y-axis) vs frequency of mutations (x-axis). E484K in S African lineage most worrying. But others affect some serum to various degrees & no such thing as "average" human when it comes to serum specificity (13/n) Image
Importantly, we only looked at RBD muts, since majority of neut activity of most sera from RBD antibodies (2nd tweet of thread). But NTD muts also important; see @10queues @mccarthy_kr @GuptaR_lab @e_andreano @McLellan_Lab: biorxiv.org/content/10.110…, medrxiv.org/content/10.110… (14/n)
This relative role of RBD & NTD mutations consistent w historical evolution of common-cold CoV-229E, where mutations concentrated in receptor-binding loops of RBD, but also in parts of NTD. Here is plot of mutational variability in CoV-229E spike: (15/n)
Read 16 tweets
18 Dec 20
In new work, we show a human coronavirus evolves to escape neutralization by antibody immunity (biorxiv.org/content/10.110…). Specifically, we studied the historical evolution of the common-cold CoV-229E to learn how #SARSCoV2 might evolve & if we might need to update vaccines. (1/n)
We first built a phylogenetic tree of CoV-229E evolution from 1984 to the present, and experimentally reconstructed the spike from viruses at 8 year intervals (1984, 1992, etc; see large black strain names in tree below). (2/n) Image
Next we tested how well human sera collected shortly after 1984 neutralized each viral spike. Below is serum from 26 yr old collected in 1985: it neutralizes 1984 virus well, but 10-fold less activity against 1992 virus & no activity against viruses after 2008. (3/n) Image
Read 17 tweets
2 Dec 20
After posting our pre-print mapping #SARS_CoV_2 mutations that escape Regeneron antibodies, been getting questions about implications for therapies/vaccines. I'd like to contextualize results. Summary is don't be alarmed, but pay attention to viral evolution. Long version: (1/n)
Antibody treatments consist of a single antibody (or in some cases a cocktail of a few) that bind viral spike. Since an antibody binds to one small patch of virus, typically a single mutation is sufficient to escape binding by an antibody. (2/n)
We know from other viruses this can happen. One of the best examples is Regeneron's trial of an antibody to treat RSV in infants (academic.oup.com/cid/advance-ar…). They ran an entire large / expensive clinical trial that failed. Retrospectively, the reason was obvious... (3/n)
Read 21 tweets
1 Dec 20
We mapped all #SARSCoV2 mutations escaping key antibodies used to treat #COVID19 (biorxiv.org/content/10.110…). Surprising observations: one amino-acid mutation escapes *both* antibodies in @Regeneron cocktail & escape mutations selected in infected patient treated w cocktail. (1/8)
Specifically, @tylernstarr, Allie Greaney, Amin Addetia, and @AdamDingens used a deep mutational scanning system to determine all mutations that escape antibodies in REGN-COV2 and LY-CoV016. You can view these complete escape maps here: jbloomlab.github.io/SARS-CoV-2-RBD… (2/8)
Surprisingly, they found a single amino-acid mutation (E406W) can escapes both antibodies in REGN-COV2 cocktail. E406W isn't in structural footprint of either antibody (see image), so mechanism is unclear. But it reduces cocktail neutralization by 100-fold. (3/8) Image
Read 8 tweets
11 Nov 20
I want to flag this important work by @SCOTTeHENSLEY, which is the best study on whether there are pre-existing antibodies to #SARSCoV2 in uninfected people that affect risk of getting #COVID19. (1/7).
Much recent speculation (eg, NY Times by @ginakolata) on if some people have pre-existing antibodies to #SARSCoV2 (eg, from common-cold CoV) that affect risk to get #COVID19. Hensley paper is a well-designed study that *actually answers* this question (2/7)
They looked at sera collected prior to #SARSCoV2. Most sera didn't have antibodies that bound #SARSCoV2 spike, but some had modest binding, mostly to S2 but a few to RBD. None of these sera were potently neutralizing, and no trend for kids to have more of them. (3/7)
Read 14 tweets
11 Sep 20
In a new study (biorxiv.org/content/10.110…), we have completely mapped mutations to #SARSCoV2 that escape human antibodies, and shown that these "escape maps" predict how virus evolves under antibody pressure & inform design of escape-resistant antibody cocktails. (1/12)
Background: antibodies that target the #SARSCoV2 receptor-binding domain (RBD) are being developed as therapeutics & vaccines aim to elicit them. Among most potent RBD antibodies are set isolated by @VUMC_Vaccines, @seth_zost & Pavlo Gilchuk (nature.com/articles/s4158…) (2/12)
Key question is what mutations to #SARSCoV2 RBD escape antibody binding. Classic way to determine this is to grow virus w antibody & see what is selected. But this approach is incomplete: any given replicate stochastically selects at most 1 of possible escape mutations. (3/12)
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!